High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis

Joint Bone Spine

Volumn 81, Issue 5, 2014, Pages 416-420

  Gardette, Anaïs ^a   Ottaviani, Sébastien ^a   Tubach, Florence ^a,b,c   Roy, Carine ^a,b,c   Nicaise Roland, Pascale ^a   Palazzo, Elisabeth ^a   Gill, Ghislaine ^a   Meyer, Olivier ^a   Dieudé, Philippe ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BICHAT HOSPITAL   (France)

^c INSERM   (France)

Author keywords

Anti CCP antibodies; Rheumatoid arthritis; Rituximab

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; METHOTREXATE; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; DAS28; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SMOKING; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; BLOOD; IMMUNOLOGY; MIDDLE AGED; URINE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RETROSPECTIVE STUDIES;

EID: 84927693600     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.06.001     Document Type: Article

References (21)

1. Cohen S.B., Emery P., Greenwald M.W., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806.
2. Emery P., Fleischmann R., Filipowicz-Sosnowska A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006, 54:1390-1400.
3. van Dongen H., van Aken J., Lard L.R., et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007, 56:1424-1432.
4. Visser K., Verpoort K.N., van Dongen H., et al. Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis. Ann Rheum Dis 2008, 67:1194-1195.
5. Marston B., Palanichamy A., Anolik J.H. B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr Opin Rheumatol 2010, 22:307-315.
6. Sellam J., Hendel-Chavez H., Rouanet S., et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 2011, 63:933-938.
7. Teng Y.K., Levarht E.W., Hashemi M., et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007, 56:3909-3918.
8. Soliman M.M., Hyrich K.L., Lunt M., et al. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. J Rheumatol 2012, 39:240-246.
9. Chatzidionysiou K., Lie E., Nasonov E., et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011, 70:1575-1580.
10. Quartuccio L., Fabris M., Salvin S., et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 2009, 48:1557-1559.
11. Isaacs J.D., Cohen S.B., Emery P., et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 2013, 72:329-336.
12. Narvaez J., Diaz-Torne C., Ruiz J.M., et al. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs. Clin Exp Rheumatol 2011, 29:991-997.
13. Solau-Gervais E., Prudhomme C., Philippe P., et al. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure. Joint Bone Spine 2012, 79:281-284.
14. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
15. van Gestel A.M., Haagsma C.J., van Riel P.L. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998, 41:1845-1850.
16. Aubart F., Crestani B., Nicaise-Roland P., et al. High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. J Rheumatol 2011, 38:979-982.
17. Potter C., Hyrich K.L., Tracey A., et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 2009, 68:69-74.
18. Braun-Moscovici Y., Markovits D., Zinder O., et al. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol 2006, 33:497-500.
19. Alessandri C., Bombardieri M., Papa N., et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF-alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004, 63:1218-1221.
20. Chen H.A., Lin K.C., Chen C.H., et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:35-39.
21. Atzeni F., Sarzi-Puttini P., Dell' Acqua D., et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 2006, 8:R3.